Advertisement
YOU ARE HERE: LAT HomeCollectionsRituxan Drug
IN THE NEWS

Rituxan Drug

FEATURED ARTICLES
BUSINESS
December 19, 2006 | Daniel Yi, Times Staff Writer
The bestselling medicine for two of the country's biggest biotech drug companies has been further linked to a rare and deadly brain infection, U.S. health officials warned Monday. The news could hurt efforts by Genentech Inc. and Biogen Idec Inc. to expand approved treatments for Rituxan. Patients taking Rituxan, a drug approved to treat rheumatoid arthritis and non-Hodgkins lymphoma, have been known to contract the rare brain infection.
ARTICLES BY DATE
BUSINESS
December 19, 2006 | Daniel Yi, Times Staff Writer
The bestselling medicine for two of the country's biggest biotech drug companies has been further linked to a rare and deadly brain infection, U.S. health officials warned Monday. The news could hurt efforts by Genentech Inc. and Biogen Idec Inc. to expand approved treatments for Rituxan. Patients taking Rituxan, a drug approved to treat rheumatoid arthritis and non-Hodgkins lymphoma, have been known to contract the rare brain infection.
Advertisement
BUSINESS
October 5, 2004 | From Bloomberg News
Genentech Inc. said it received a request for information from the U.S. attorney's office about its promotion of the cancer drug Rituxan. Genentech of South San Francisco received the subpoena as part of a civil and criminal investigation by the U.S. attorney in Philadelphia, Genentech said. A Genentech spokeswoman declined to comment on the reasons for the investigation. Genentech shares rose 83 cents to $53.99 on the New York Stock Exchange before the subpoena was disclosed.
BUSINESS
August 18, 2005 | From Reuters
Genentech Inc., Swiss drug maker Roche Holding and Biogen Idec Inc. said they had completed their U.S. marketing application to expand use of their drug Rituxan to patients never before treated for non-Hodgkin's lymphoma. The popular medicine was approved in the United States in 1997 for patients with the low-grade form of that type of lymphoma who had failed to benefit from other standard therapies.
BUSINESS
August 18, 2005 | From Reuters
Genentech Inc., Swiss drug maker Roche Holding and Biogen Idec Inc. said they had completed their U.S. marketing application to expand use of their drug Rituxan to patients never before treated for non-Hodgkin's lymphoma. The popular medicine was approved in the United States in 1997 for patients with the low-grade form of that type of lymphoma who had failed to benefit from other standard therapies.
BUSINESS
October 11, 2001 | From Bloomberg News
Idec Pharmaceuticals Corp. said U.S. sales of its cancer drug Rituxan, which the company developed and markets with Genentech Inc., rose 77% in the third quarter. Sales of the drug rose to $205 million in the third quarter from $115.5 million a year earlier. Analysts had expected U.S. sales of $195 million to $200 million for the non-Hodgkin's lymphoma drug, the company's only marketed product.
BUSINESS
July 12, 2001 | From Bloomberg News
Shares of Genentech Inc. and Idec Pharmaceuticals Corp. fell Wednesday after the biotechnology companies reported lower-than-expected sales of the cancer drug Rituxan, which they jointly market. However, South San Francisco-based Genentech, the world's oldest biotechnology company, said second-quarter profit rose 28%. Profit from operations rose to $101.5 million, or 19 cents a share, from $79.6 million, or 15 cents a share, a year earlier. Revenue rose 24% to $515.9 million from $415.8 million.
BUSINESS
September 25, 1998
Genentech Inc. will likely report 1998 earnings of $1.30 a share, beating forecasts. South San Francisco-based Genentech, which is majority-owned by Roche Holding, reported 1997 earnings of $1.02 a share. Analysts had forecast profit of $1.28. Genentech Chief Financial Officer Louis Lavigne Jr. said profit will likely exceed forecasts, thanks to strong sales of Rituxan, a drug the company developed with Idec Pharmaceuticals Corp. and started selling in December 1997.
BUSINESS
May 2, 2007 | From Reuters
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.
BUSINESS
October 5, 2004 | From Bloomberg News
Genentech Inc. said it received a request for information from the U.S. attorney's office about its promotion of the cancer drug Rituxan. Genentech of South San Francisco received the subpoena as part of a civil and criminal investigation by the U.S. attorney in Philadelphia, Genentech said. A Genentech spokeswoman declined to comment on the reasons for the investigation. Genentech shares rose 83 cents to $53.99 on the New York Stock Exchange before the subpoena was disclosed.
BUSINESS
October 11, 2001 | From Bloomberg News
Idec Pharmaceuticals Corp. said U.S. sales of its cancer drug Rituxan, which the company developed and markets with Genentech Inc., rose 77% in the third quarter. Sales of the drug rose to $205 million in the third quarter from $115.5 million a year earlier. Analysts had expected U.S. sales of $195 million to $200 million for the non-Hodgkin's lymphoma drug, the company's only marketed product.
BUSINESS
July 12, 2001 | From Bloomberg News
Shares of Genentech Inc. and Idec Pharmaceuticals Corp. fell Wednesday after the biotechnology companies reported lower-than-expected sales of the cancer drug Rituxan, which they jointly market. However, South San Francisco-based Genentech, the world's oldest biotechnology company, said second-quarter profit rose 28%. Profit from operations rose to $101.5 million, or 19 cents a share, from $79.6 million, or 15 cents a share, a year earlier. Revenue rose 24% to $515.9 million from $415.8 million.
BUSINESS
March 1, 2006 | From Reuters
Genentech Inc. and Biogen Idec Inc. on Tuesday said U.S. regulators had approved their non-Hodgkin's lymphoma drug Rituxan as a treatment for rheumatoid arthritis. The drug was approved in combination with methotrexate for patients with moderatelyto-severely active rheumatoid arthritis who had failed to get adequate relief from previous treatments involving at least one other medicine.
BUSINESS
July 21, 1998 | From Bloomberg News
Genentech Inc., one of the world's largest biotechnology companies, halted a study to expand use of its clot buster Activase after it failed to prove effective for stroke patients three to five hours after stroke symptoms began. An interim analysis by outside experts said there was an "extremely small statistical chance" of demonstrating any benefit by testing another 500 people, as had been planned.
Los Angeles Times Articles
|